Novocure Ltd (NASDAQ:NVCR) — Market Cap & Net Worth
Market Cap & Net Worth: Novocure Ltd (NVCR)
Novocure Ltd (NASDAQ:NVCR) has a market capitalization of $1.95 Billion ($1.95 Billion) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6409 globally and #1954 in its home market, demonstrating a 3.54% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Novocure Ltd's stock price $17.85 by its total outstanding shares 115820940 (115.82 Million). Review Novocure Ltd total liabilities to assess the company's total debt and financial obligations.
Novocure Ltd Market Cap History: 2015 to 2026
Novocure Ltd's market capitalization history from 2015 to 2026. Data shows change from $2.59 Billion to $2.07 Billion (-2.43% CAGR).
Index Memberships
Novocure Ltd is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.08% | #156 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #695 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.70 Trillion | 0.12% | #99 of 263 |
Weight: Novocure Ltd's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Novocure Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Novocure Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.29x
Novocure Ltd's market cap is 2.29 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $909.19 Million | $82.89 Million | -$131.84 Million | 10.97x | N/A |
| 2017 | $2.34 Billion | $177.03 Million | -$61.66 Million | 13.22x | N/A |
| 2018 | $3.88 Billion | $248.07 Million | -$63.56 Million | 15.63x | N/A |
| 2019 | $9.76 Billion | $351.32 Million | -$7.23 Million | 27.78x | N/A |
| 2020 | $20.04 Billion | $494.37 Million | $19.81 Million | 40.54x | 1011.80x |
| 2021 | $8.70 Billion | $535.03 Million | -$58.35 Million | 16.25x | N/A |
| 2022 | $8.50 Billion | $537.84 Million | -$92.53 Million | 15.80x | N/A |
| 2023 | $1.73 Billion | $509.34 Million | -$207.04 Million | 3.40x | N/A |
| 2024 | $3.45 Billion | $605.22 Million | -$168.63 Million | 5.70x | N/A |
| 2025 | $1.50 Billion | $655.35 Million | -$136.23 Million | 2.29x | N/A |
Competitor Companies of NVCR by Market Capitalization
Companies near Novocure Ltd in the global market cap rankings as of June 18, 2026.
Key companies related to Novocure Ltd by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #149 globally with a market cap of $153.89 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #212 globally with a market cap of $115.24 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #236 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
- Medtronic PLC (NYSE:MDT): Ranked #252 globally with a market cap of $100.32 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #149 | Abbott Laboratories | NYSE:ABT | $153.89 Billion | $88.50 |
| #212 | Stryker Corporation | NYSE:SYK | $115.24 Billion | $301.14 |
| #236 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
| #252 | Medtronic PLC | NYSE:MDT | $100.32 Billion | $78.14 |
Novocure Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Novocure Ltd's market cap moved from $2.59 Billion to $ 2.07 Billion, with a yearly change of -2.43%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.07 Billion | +38.05% |
| 2025 | $1.50 Billion | -56.61% |
| 2024 | $3.45 Billion | +99.60% |
| 2023 | $1.73 Billion | -79.65% |
| 2022 | $8.50 Billion | -2.30% |
| 2021 | $8.70 Billion | -56.61% |
| 2020 | $20.04 Billion | +105.34% |
| 2019 | $9.76 Billion | +151.70% |
| 2018 | $3.88 Billion | +65.74% |
| 2017 | $2.34 Billion | +157.32% |
| 2016 | $909.19 Million | -64.89% |
| 2015 | $2.59 Billion | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Novocure Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.95 Billion USD |
| MoneyControl | $1.95 Billion USD |
| MarketWatch | $1.95 Billion USD |
| marketcap.company | $1.95 Billion USD |
| Reuters | $1.95 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Novocure Ltd
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TT… Read more